Compound 51 also inhibited DDR1-mediated cadherin switching, suppressed colony development of pancreatic cancer cells, exhibited good PK properties, and displayed a promising therapeutic activity through oral administration in orthotropic syngeneic pancreatic cancer models. Here, CDH17 is linked to pancreatic neoplasm.